Pancreatic cancer enhances HER2 signaling through DUSP6 to circumvent therapeutic MAPK inhibition.

被引：0
|
作者：
Bulle, Ashenafi Shiferaw [1 ,2 ]
Seehar, Kuljeet [1 ,2 ]
Bansod, Sapana [1 ,2 ]
Chen, Yali [1 ,2 ]
Hung-Po, Chen [1 ,2 ]
Dodhiawala, Paarth B. [1 ,2 ]
Li, Lin [1 ,2 ]
Somani, Vikas [1 ,2 ]
Mudd, Jacqueline [1 ,2 ]
Fields, Ryan C. [1 ,2 ]
Knoerzer, Deborah [3 ]
Wang-Gillam, Andrea [1 ,2 ]
Kian-Huat, Lim [1 ,2 ]
机构：
[1] Washington Univ, Sch Med, Barnes Jewish Hosp, St Louis, MO USA
[2] Washington Univ, Sch Med, Alvin J Siteman Comprehens Canc Ctr, St Louis, MO USA
[3] 23BioMed Valley Discoveries, Kansas City, MO USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
DS-8201a; DUSP6; HER2; KRAS; ulixertinib; pancreatic ductal adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5333
引用
收藏
页数：1
相关论文
共 50 条
  • [41] TNF-MK2 signaling drives protective autophagy following MAPK pathway inhibition in pancreatic cancer
    Khawar, Iftikhar Ali
    Wei, Qing
    Chen, Timothy Hung-Po
    Lin, Lin
    Grierson, Patrick M.
    Lim, Kian-Huat
    CANCER RESEARCH, 2023, 83 (07)
  • [42] Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
    Hanker, Ariella B.
    Estrada, Monica Valeria
    Bianchini, Giampaolo
    Moore, Preston D.
    Zhao, Junfei
    Cheng, Feixiong
    Koch, James P.
    Gianni, Luca
    Tyson, Darren R.
    Sanchez, Violeta
    Rexer, Brent N.
    Sanders, Melinda E.
    Zhao, Zhongming
    Stricker, Thomas P.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2017, 77 (12) : 3280 - 3292
  • [43] Dual-specificity phosphatase 6 (Dusp6), a negative regulator of FGF2/ERK1/2 signaling, enhances 17β-estrodial-induced cell growth in endometrial adenocarcinoma cell
    Zhang, Hui
    Guo, Qiufen
    Wang, Chong
    Yan, Lei
    Fu, Yibing
    Fan, Mingjun
    Zhao, Xingbo
    Li, Mingjiang
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2013, 376 (1-2) : 60 - 69
  • [44] MEK inhibition leads to elevated HER3:PI3K in EGFR or HER2 driven cancer through feedback induction of HER1:3 and HER2:3 dimers
    Hoe, Nicholas
    Mateling, Michael
    Ma, Yating
    Jin, Kelly
    Zhou, JinYao
    Kirkland, Richard
    Kuy, Crystal
    Liu, Xinjun
    Kim, Phillip
    Singh, Sharat
    CANCER RESEARCH, 2013, 73 (08)
  • [45] HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells
    Hirata, A
    Hosoi, F
    Miyagawa, N
    Ueda, S
    Naito, S
    Fujii, T
    Kuwano, N
    Ono, M
    CANCER RESEARCH, 2005, 65 (10) : 4253 - 4260
  • [46] Inhibition of GAS6/AXL improves efficacy of HER2 inhibitor trastuzumab in uterine serous cancer
    Tankou, Joan
    Toboni, Michael
    Kuroki, Lindsay
    McCourt, Carolyn
    Hagemann, Andrea
    Thaker, Premal
    Powell, Matthew
    Khabele, Dineo
    Mutch, David
    Fuh, Katherine
    GYNECOLOGIC ONCOLOGY, 2021, 162 : S190 - S190
  • [47] Selective inhibition of HER2 signaling pathway reveals novel functions of FOXA1 in breast cancer.
    Katika, Madhumohan
    Martin, Ruthmma
    Siv, Gilfillan
    Borresen-Dale, Anne Lise
    Lopez, Sandra
    Hurtado, Toni
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [48] Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
    Yang, Yun
    Ren, Feng
    Tian, Ziyin
    Song, Wei
    Cheng, Binfeng
    Feng, Zhiwei
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [49] Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells
    Mcdermott, Martina S. J.
    Canonici, Alexandra
    Ivers, Laura
    Browne, Brigid C.
    Madden, Stephen F.
    O'Brien, Neil A.
    Crown, John
    O'Donovan, Norma
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 50 (06) : 2221 - 2228
  • [50] Dual inhibition of FGFR4 and HER2/EGFR with Lapatinib improves targeting of Erk and Akt signaling in HER2+breast cancer cells
    Beardsley, Jordan
    Goode, Joseph
    Altomare, Deborah
    CANCER RESEARCH, 2024, 84 (09)
12345